Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Prothena to Participate in Upcoming September Investor Conferences

Prothena Corporation plc
Posted on: 30 Aug 16

DUBLIN, Ireland, Aug. 30, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development, and commercialization of novel protein immunotherapies, today announced that members of its senior management team will present and participate in several upcoming investor conferences: 

  • Credit Suisse Antibody Day  on September 7, 2016 at 12:00 PM ET in New York, NY
  • Citi's   11th Annual Biotech Conference  on September 8, 2016 in Boston, MA
  • Morgan Stanley Global Healthcare Conference  on September 12, 2016 at 8:45 AM ET in New York, NY
  • The  Ladenburg Thalmann 2016 Healthcare Conference  on September 27, 2016 at 10:00 AM ET in New York, NY

A live webcast of the company presentations can be accessed under the Investors tab in the Events and Presentations section of the Company's website at  www.prothena.com . Following the live presentations, a replay of each webcast will be available on the Company's website for at least 90 days following the presentation date.

About Prothena

Prothena Corporation plc is a global, late-stage clinical biotechnology company seeking to fundamentally change the course of progressive diseases with its clinical pipeline of novel therapeutic antibodies. Fueled by its deep scientific understanding built over decades of research in protein misfolding and cell adhesion - the root causes of many serious or currently untreatable amyloid and inflammatory diseases - Prothena has advanced several drug candidates into clinical trials while pursuing discovery of additional novel therapies.  Our pipeline of antibody-based product candidates targets a number of potential indications including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002) and inflammatory diseases, including psoriasis (PRX003), and ATTR amyloidosis (PRX004). For more information, please visit the company's web site at  www.prothena.com

For more information, please visit the company's web site at  www.prothena.com

Contacts

Investors: Tran Nguyen, CFO
650-837-8535, IR@prothena.com 

Media: Ellen Rose
650-922-2405, ellen.rose@prothena.com 



This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Prothena Corporation plc via GlobeNewswire
HUG#2038069
GlobeNewswire
globenewswire.com

Last updated on: 31/08/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.